During a poster presentation at ASCO 2023, Prof Dr Cora Sternberg, a medical oncologist from Weill Cornell Medicine in New York, shared her findings from the SAUL study. This study involved over 1000 patients with locally advanced or metastatic urothelial cancer who had failed previous treatment, and were subsequently administered atezolizumab until clinical benefit was no longer observed. The primary objective of the study was to assess safety.
With the educational support of:
